Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Despite being a first-line treatment for adolescent depression and anxiety, antidepressant drugs appear to have questionable efficacy and carry an increased risk of adverse effects in this population.

Duloxetine is an antidepressant, with a specific batch having been recalled due to the presence of potentially cancer-causing impurities.

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

This paper reviews recent findings on the pharmacogenetics of antidepressant drugs and future clinical applications. Ultimately, these studies should lead to the use of genetic testing to guide ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...